<DOC>
	<DOCNO>NCT00411580</DOCNO>
	<brief_summary>This study evaluate safety tolerability Aß-specific antibody response CAD106 patient mild moderate Alzheimer 's Disease . Patients also 2 year follow-up ass disease progression drug administer .</brief_summary>
	<brief_title>Safety Tolerability Study Patients With Mild Moderate Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>male and/or female patient 50 80 year age ( inclusive ) . female patient must without childbearing potential ( postmenopausal surgically sterilize ) . diagnosis dementia Alzheimer 's type accord DSMIV criterion ( Diagnostic Statistical Manual Mental Disorders , 4th edition ) . mild moderate AD confirm MiniMental State Exam score 16 26 ( inclusive ) screening . able provide write informed consent responsible caregiver provide write assent prior study participation . For patient declare mentally incompetent , legal representative need provide informed consent behalf . previously participate AD vaccine study receive active treatment history presence active autoimmune and/or cerebrovascular disease history presence seizure , acute chronic inflammation clinically relevant atopic condition , suffer neurodegenerative disease and/or psychiatric disorder ( exception successfully treat depression ) immunosuppressive treatment include systemic steroid obtain vaccination ( e.g . influenza ) within 4 week first study drug injection advance , severe , progressive unstable disease might interfere safety patient start treatment psychotropic medication within 3 month ( 4 week SSRIs new antidepressant without anticholinergic property ) prior randomization exception mild hypnotic drug ( e.g . zolpidem , zopiclone , oxazepam ) low dos neuroleptic drug ( e.g . 2 mg risperidone ) . Patients , stable treatment cholinesteraseinhibitors ( ChEIs ) and/or memantine least 3 month , and/or SSRIs and/or newer antidepressant ( without anticholinergic property ) least 4 week randomization , include study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Mild , moderate Alzheimer 's Disease ( AD ) , Aß-specific antibody , CAD106</keyword>
</DOC>